Sep 2026· Vaccine Insights· Vol 5, pp. 411–416· 0 citations
TL;DR
The obstacles to demonstrating transmission-blocking efficacy are outlined, from the absence of standardized correlates of protection to the limitations of animal and trial models, and how controlled human infection models, household studies, and field trials could help generate evidence to support regulatory engagement and licensure are considered.
Abstract
Mucosal vaccines are widely proposed as a way to block respiratory virus transmission more effectively than systemic vaccines, yet supporting clinical evidence remains scarce. This Commentary outlines the obstacles to demonstrating transmission-blocking efficacy, from the absence of standardized correlates of protection to the limitations of animal and trial models, and considers how controlled human infection models, household studies, and field trials could help generate this evidence to support regulatory engagement and licensure.
This Perspective describes the Vaccine Integrity Project, established in 2025 in response to concerns about the stability and integrity of US vaccine policy due to disruptions to the work of the Advisory Committee on Immunization Practices; outlines the process for the 2026-2027 evidence review; and summarizes key fi...
S. Fryhofer, Andrea M. Garcia, M. Osterholm et al.· Journal of the American Medi...· 1 citation
Natural Cryptosporidium infection causes development of protective immunity. Live-attenuated vaccines stimulate both adaptive and "trained" innate immune responses. With advances in parasite genetics, target identification, and in vitro cultivation, we now propose development of a live-attenuated vaccine for cryptospor...
A. C. White, S. M. Dann, Alejandro Castellanos-González· Journal of Infectious Diseas...· 0 citations
Dengue is among the fastest-growing mosquito-borne viral infections worldwide and continues to pose a major public health challenge because no approved antiviral treatment is available. As a result, vaccination has become a cornerstone of dengue prevention. Several vaccine candidates have progressed through clinical de...
Vydeti Mounika, E. Sirisha, Srikakulapu Balu et al.· International journal of med...· 0 citations
Hantaviruses are zoonotic threats that can cause hemorrhagic fever with renal syndrome and severe cardiopulmonary syndrome. Despite disease severity, there are no approved vaccines or therapeutics available for the prevention or management of hantavirus infections. Here, we discuss advances in the development of vaccin...
Martin Ferrié, Johan Neyts· Cell Host and Microbe· 0 citations
Andes virus, the principal etiological agent of hantavirus cardiopulmonary syndrome in South America, is a zoonotic pathogen associated with case fatality rates of up to 40%. Despite its high clinical burden and unique capacity for person-to-person transmission among hantaviruses, no licensed vaccines or specific ant...
Jorge T. González, Camila Kossack, Jose L. Garrido et al.· Biological Research· 0 citations
ABSTRACT Mosquito-borne viral diseases are expanding globally, yet programmatic access to dengue and chikungunya vaccines remains limited or uneven in many high-risk settings. Using country-level classifications of regulatory approval and national immunization program inclusion, we identify substantial gaps between vac...
Keng-Tee Kok, Dong-Kui Mu, Bing-Hui Wang et al.· Human Vaccines & Immunothera...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
